{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.8","upperLimit":"7.8","value":"3.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"}],"units":"Participants"}],"description":"Overall survival is defined as the time from enrolment until death due to any cause. The Kaplan-Meier method was used to estimate overall survival.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive SB-715992 IV over 1 hour on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.\n\nispinesib: Given IV\n\nlaboratory biomarker analysis: Correlative studies\n\npharmacological study: Correlative studies","id":"OG000","title":"Treatment (Ispinesib)"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"Up to 18 months","title":"Median Overall Survival of SB-715992","type":"SECONDARY","unitOfMeasure":"months"}